It is not yet FDA- approved, but its Phase 3 program is now producing the largest weight-loss numbers ever recorded for a drug and, critically, meaningful improvements in the conditions obesity drives: type 2 diabetes, sleep apnea, osteoarthritis, and liver disease
**Quick calculator (24mg vial at 8mg/ml):** | Weekly Dose | Volume per Injection | Syringe Units | Doses per Vial | |------------|---------------------|---------------|----------------| | 4mg | 0.50ml | 50 units | 6 doses | | 8mg | 1.00ml | 100 units | 3 doses | | 12mg | 1.50ml | Split: 75 units x2 | 2 doses | ### How to Reconstitute Retatrutide 30mg Vial The 30mg vial is the most cost-effective option, especially for patients at higher therapeutic doses
6 Of individuals who received liraglutide only, 33% maintained 5% weight loss and 16% maintained 10% weight loss
Phase 3 trials (the TRIUMPH programme, registered on ClinicalTrials.gov) are currently underway, evaluating retatrutide across broader populations including those with cardiovascular disease, type 2 diabetes, and obesity-related complications
